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Abstract Clostridium difficile infection (CDI) is a major
cause of nosocomial diarrhea. CDI is known to develop after
antibiotic administration, but anti-tuberculosis agents have
rarely been implicated. We documented an outbreak caused
by a highly rifampicin-resistant C. difficile strain of poly-
merase chain reaction (PCR) ribotype 046 in patients with
active tuberculosis.
Introduction
Clostridium difficile infection (CDI), the most common
infectious cause of hospital-acquired diarrhea, is usually
preceded by the use of antibiotics such as fluoroquinolones
(FQ), cephalosporins, broad-spectrum penicillins, and
clindamycin [1]. Anti-tuberculosis drugs are not commonly
associated with the development of CDI [2–5]. Recently, FQ
have been linked to CDI, particularly those cases caused by
polymerase chain reaction (PCR) ribotype 027 [6, 7]. The
objective of our study was to determine the characteristics of
C. difficile isolates associated with an outbreak of infection
in a tuberculosis unit. Patients were hospitalized in the
Specialized Hospital of Lung Diseases and Tuberculosis
(SHLDT) in Bystra, South Poland. The clinical findings
were also assessed.
Materials and methods
Setting and study design
This study was conducted in the 250-bed SHLDT harboring
a 46-bed tuberculosis unit, located in South Poland. During
the study period, a total of 8,158 patients were hospitalized
in the SHLDT. From September 2009 through December
2010, CDI was suspected in 23 symptomatic patients. CDI
was diagnosed in ten patients, corresponding to an incidence
of 12.3/10,000 patients admitted to the SHLDT. CDI was
diagnosed by an immunoenzymatic assay (C. difficile TOX
A/B II, TechLab, Blacksburg, VA, USA) and C. difficile
culture for patients who developed diarrhea. The clinical
characteristics of the ten patients were observed prospec-
tively and C. difficile isolates from the patients were collect-
ed for further study.
Definition of CDI
Diarrhea was defined as the passage of three or more un-
formed stools in 24 h or less. CDI was diagnosed when
patients had diarrhea and C. difficile toxin(s) was/were
detected in fecal samples and/or cultures revealed the pres-
ence of C. difficile. We defined hospital-acquired CDI
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(HA-CDI) when diarrhea developed at least 48 h after
hospitalization or within 2 months of hospital discharge if
a patient had a complicated clinical status involving admis-
sion to the Intensive Care Unit or surgical intervention [8].
Data collection
The clinical data collected in this study were age, length of
hospitalization, medication history, underlying conditions,
and the use of antibiotics or chemotherapeutics, especially
anti-tuberculosis medication. All adults (mean age
64.3 years) who were suspected of CDI hospitalized at the
SHLDT in the period between September 09, 2009 and
December 31, 2010 were included in the study. Stool char-
acteristics, frequency of defecation, and abdominal pain
were monitored.
Microbiological studies
All fecal samples from ten C. difficile toxin-positive diar-
rheic patients were inoculated anaerobically on C.
difficile-selective cycloserine–cefoxitin agar plates (CLO,
bioMérieux SA, Marcy l’Etoile, France). Colonies were
identified as C. difficile on the basis of characteristic growth
on selective medium, yellow-green fluorescence under UV
light (365 nm), the specific odor, and API 20A (bioMérieux
SA, Marcy l’Etoile, France). PCR assays to detect tcdA and
tcdB genes and the specific deletion in the tcdA gene were
conducted as previously described [9]. Primers described by
Stubbs et al. were used for amplification of the binary toxin
genes cdtA and cdtB [10]. Three strains were included in this
study as controls: toxigenic C. difficile VPI 10463 (A+B+),
non-toxigenic C. difficile NIHBRRIGS 8050 (A−B−), and
C. difficile GAI 95601 (A−B+) (from H. Kato, Institute of
Anaerobic Bacteriology, Gifu University School of Medi-
cine, Gifu, Japan). PCR ribotyping was performed as de-
scribed by Stubbs et al. [11]. Banding patterns were
compared with those of the library of PCR ribotypes at the
Anaerobe Reference Laboratory (ARU), Cardiff, Wales,
UK. Strains belonging to different PCR ribotypes were used
as internal controls.
Antimicrobial drug susceptibility testing
Cultures of C. difficile strains on Columbia agar plates
(bioMérieux SA, Marcy l’Etoile, France) were suspended
and adjusted to an OD950 of 1 on the McFarland scale (using
a bioMérieux ATB1550 densitometer) and grown as lawns on
Brucella agar plates. Plastic strips (E-test, bioMérieux SA,
Marcy l’Etoile, France) with gradients of antibiotics,
clindamycin (CL), erythromycin (EM), ciprofloxacin (CI),
moxifloxacin (MX), metronidazole (MTZ), vancomycin
(VA), and rifampicin (RI), were placed on each plate and
incubated anaerobically at 37 °C for 48 h, according to the
manufacturer’s instructions. According to the Clinical and
Laboratory Standards Institute (CLSI) recommendations
[12], antibiotic resistance was defined as follows: minimum
inhibitory concentration (MIC) ≥8.0 mg/L for clindamycin
and erythromycin, MIC ≥4.0 mg/L for ciprofloxacin and
moxifloxacin. Resistance to metronidazole and vancomycin
was defined according to the European Committee on Anti-
microbial Susceptibility Testing (EUCAST): for metronida-
zole MIC≥1mg/L and for vancomycinMIC>2mg/L [13]. No
CLSI guidelines exist for determining the susceptibility of C.
difficile to the rifamycins, so these ranges were determined
based on the natural breakpoints observed previously, and
rifampin susceptibility was categorized according to the MICs
determined (≤0.002 μg/mL, 0.003–32 μg/mL, and >32 mg/L)
[14]. Quality control strains (Bacteroides fragilis NCTC
11295, B. thetaiotaomicron ATCC 29741, Escherichia coli




The demographic data, medication history, and clinical
and laboratory characteristics of CDI are presented in
Table 1. Ten patients with an age range from 48 to
86 years (median age 64.3 years) were diagnosed with
a CDI between September 2009 and December 2010.
There were four women and six men: six patients were
hospitalized in the tuberculosis unit and four patients in
other units: pulmonary (n=2), internal medicine (n=1),
and thoracic surgery (n=1). Of the ten patients, five had
active pulmonary tuberculosis as diagnosed by sputum
smear and culture. These patients were treated with anti-
tuberculosis agents, including isoniazid, rifampicin, and
pyrazinamide. Watery diarrhea was observed in all pa-
tients, and provided the major clinical manifestation.
Three patients developed CDI recurrence. Five patients
died because of CDI and the attributed mortality was
50 % (5/10).
Microbiological analysis
Ten C. difficile strains were available for investigation. All
ten isolates contained tcdA and tcdB genes. The PCR
detecting the repeated sequences in the toxin A gene was
positive for a single isolate and generated a 700-bp product
similar to that obtained for the Japanese control GAI 95601
C. difficile strain. PCR ribotyping classified the ten isolates
according to their ribotypes: 046 (n=7), 001 (n=1), 002
(n=1), and 017 (n=1). All strains were resistant to
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ciprofloxacin (CI; MIC≥32 mg/L), eight strains to
moxifloxacin (MX; MIC≥32 mg/L), seven strains to
clindamycin (CM; MIC≥256 mg/L) and erythromycin
(EM; MIC≥256 mg/L), and seven to rifampicin (RI;
MIC≥32 mg/L). All strains were susceptible to metronida-
zole (MZT; MIC range 0.047–0.38 mg/L). The MIC range
for vancomycin (VA) was 0.75–1 mg/L. Three strains had
reduced susceptibility to vancomycin (MIC=1 mg/L)
(according to the EUCAST breakpoints). All strains be-
longing to PCR ribotype 046 were highly resistant to
moxif loxacin , c l indamycin , erythromycin , and
rifampicin.
Discussion
CDI caused by C. difficile is a major hospital problem.
During the past decade, the hypervirulent ribotype 027
strain, expressing the binary toxin, caused outbreaks in
North America and Europe [6, 7]. PCR ribotype 046 was
less commonly detected in a European survey performed in
2008; it was found in 2 % of all the tested isolates, whereas
types 014/020, 001, and 078 belonged to the most frequent-
ly encountered types [8]. Only five strains belonging to PCR
ribotype 046 were found in the University Hospital in War-
saw, Poland, between 2004 and 2006 [9]. All historic strains
Table 1 Clinical summary for ten cases of Clostridium difficile infection (CDI) in the Specialized Hospital of Lung Diseases and Tuberculosis










Other AB Date of
diagnostic
CDI





(R) or RI (S)
27.11.09–17.12.09 82/F/CD14 TBU Non-active TB,
atherosclerosis,
hypertension





13.10.09–04.01.10 86/F/CD12 TBU AP TB, chronic
congestive
heart diseases









RI, I, P – 11.12.09 Diarrhea – 046/RI (R)














RI, I, P – 30.12.09 Recurrent severe
diarrhea
Yes 046/RI (R)
19.11.09–12.02.10 51/M/CD4 TBU AP TB,
pulmonary
mycetoma
RI, I, P CI 12.01.10 Diarrhea – 046/RI (R)





25.02.10 Diarrhea – 046/RI (R)






22.03.10 Severe diarrhea Yes 017/RI (R)





– AMOX, TX 30.12.10 Diarrhea – 001/RI (S)
14.09.10–23.09.10 69/M/CD50 TS Lung tumor – CEF 23.09.10 Diarrhea – 002/RI (S)
AB antibiotics, CDI C. difficile infection, TBU tuberculosis unit, INT internal unit, PUL pulmonology, TS thoracic surgery, TB tuberculosis, AP TB
active pulmonary tuberculosis, RI rifampicin, I isoniazid, P pyrazinamide, AMOX amoxicillin, CI ciprofloxacin, CM clindamycin, MZN metroni-
dazole, TX trimethoprim/sulfamethoxazole, CEF cefazolin (perioperative prophylaxis), RI (R) rifampicin resistant, RI (S) rifampicin sensitive
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were highly resistant to clindamycin and erythromycin (MICs
≥256 mg/L), but fully susceptible to moxifloxacin and rifampi-
cin (unpublished data). In our present study, resistance to
moxifloxacin was found in all strains belonging to PCR ribotype
046. Resistance to newer fluoroquinolones has been described
not only in the hypervirulent strain 027, but also in other
emerging PCR ribotypes circulating in hospital settings [15, 16].
Anti-tuberculosis agents are very rarely associated with
CDI [2–4]. Agents such as isoniazid and pyrazinamide have
little or no effect on the intestinal flora, but rifampicin has an
antibiotic effect on a wide range of bacteria [17]. C. difficile
is usually highly resistant to rifampicin, and rifamycin de-
rivatives have been used for CDI treatment [18]. The emer-
gence of rifampicin-resistant C. difficile has been reported in
patients with prolonged rifampicin use [19]. In our study, all
PCR ribotype 046 strains isolated from patients with
prolonged rifampicin therapy were highly resistant to this
drug. Multidrug resistance (i.e., resistance to clindamycin,
moxifloxacin, and rifampin) was limited primarily to
ribotype 027 isolates [16].
Our findings suggested that: (1) patients who are treated
with anti-tuberculosis agents, especially rifampicin, who de-
veloped acute diarrhea during or after therapy should be
evaluated for CDI, (2) treatment with rifampicin can lead to
high-level resistance to rifampicin inC. difficile strains, (3) the
emergence of multidrug-resistant C. difficile PCR ribotype
046 may be detrimental to anti-tuberculosis chemotherapy.
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